Compare Bath & Body Works Inc (BBWI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Bath & Body Works Inc trades at $18.3 (market cap $3.81B), while State Street SPDR S&P Biotech ETF trades at $159.14. The key difference: Bath & Body Works Inc pays a 4.24% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Bath & Body Works Inc nearer its low. Which is the better fit depends on your goals.
| BBWI | XBI | |
|---|---|---|
Market Cap | $3.81B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $31.87 | $164.28 |
52-Week Low | $14.85 | $86.92 |
Enterprise Value | $7.70B | — |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $18.48, down 4.35% today, reflecting bearish technical signals but attractive valuations with a P/E of 5.36 and P/S of 0.54. Recent earnings show mixed results, with Q1 2026 beating estimates, while revenue has declined over five years. The company maintains strong gross margins above 43% and positive cash flow, supported by strategic expansions into Brazil and a partnership with Ulta Beauty announced in June 2026.
The stock presents a value opportunity given low multiples and analyst consensus price target of $22.11, though risks include persistent revenue declines, high debt levels, and negative shareholder equity. Investor sentiment is cautiously optimistic amid turnaround efforts, but technical weakness suggests near-term pressure.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
